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Background. Transoral robotic surgery (TORS) is an emerging treatment option for the treatment of head and neck malignancies,
particularlyfororopharyngealsquamouscellcarcinoma(OPSCC).Preliminarystudieshavedemonstratedexcellentoncologicand
functionaloutcomesthathaveledtoaresurgenceofinterestintheprimarysurgicalmanagementofOPSCC.Theaimofthepresent
study was to review the evidence base supporting the use of TORS in OPSCC. Methods. Studies evaluating the application of TORS
in the treatment of head and neck squamous cell carcinoma (HNSCC), and more speciﬁcally OPSCC, were identiﬁed for review.
Further searches were made of reference lists for complete evaluation of minimally invasive surgery (MIS) in treating OPSCC.
Results. Seventeen results relating to the application of TORS in treatment of OPSCC were identiﬁed. Further results relating to
the role of transoral laser microsurgery (TLM) in OPSCC were included for review. Feasibility, oncologic, and functional data is
summarized and discussed. Discussion. Management strategies for patients with OPSCC continue to evolve. Minimally invasive
surgical techniques including TORS and TLM oﬀer impressive functional and oncologic outcomes particularly for patients with
early T-classiﬁcation and low-volume regional metastatic disease. Potential exists for treatment deintensiﬁcation, particularly in
patients who are HPV positive.
1.Introduction
Approximately 500,000 new cases of head and neck squa-
mouscellcarcinoma(HNSCC)arediagnosedeachyearmak-
ing HNSCC the 6th most common cancer worldwide [1].
The rate of HNSCC has been increasing recently secondary
toanepidemic ofhumanpapillomavirus- (HPV-)related or-
opharyngeal squamous cell cancer (OPSCC).
These trends, which have seen rates of OPSCC as much
as double over the last three decades in some countries, have
been associated with a shift in demographics to a younger
population that is typically high functioning with lower
rates of comorbid illness [2]. Combined with lower rates
of smoking and alcohol abuse and an intrinsic improved
response rate of HPV-related OPSCC to curative treatment
regimens, the overall and disease-free survival rates in
this patient group are signiﬁcantly higher than previously
observed. As such, long-term quality of life considerations
have been made even more relevant to the multidisciplinary
team coordinating the care of these patients.
These new developments in the pathogenesis of HNSCC,
and in particular OPSCC, are occurring in the context of
large-scaleparadigmshiftsoverthepasttwodecadestowards
organ preservation treatment protocols. The Veterans Aﬀairs
laryngeal cancer study published in 1991 began the era of
organ preservation and led to the application of primary
radiation approaches to other subsites such as the orophar-
ynx [3]. Although a randomized controlled trial of primary
radiation versus surgery for oropharyngeal cancer has not
been carried out, several retrospective analyses have demon-
strated less major complications and improved functional
outcomes with radiation compared to traditional primary2 ISRN Oncology
surgical approaches. These results have contributed to the
widespread adoption of primary nonsurgical treatment in
patients with OPSCC.
Minimally invasive surgery (MIS) for HNSCC continues
to be extensively reported within the head and neck litera-
ture, driven by the desire to oﬀer a less morbid alternative
tochemoradiation.Thesetechniqueshaveincludedtransoral
laser microsurgery (TLM) and more recently, transoral
robotic surgery (TORS). TORS was ﬁrst introduced into the
literature by Weinstein et al. in 2005 with their case report
of a supraglottic laryngectomy performed in a canine model
[4]. The adaptation of this preexisting robotic technology
to a new clinical application provided a watershed moment
in the evolution of treatment options for the surgical
management of head and neck aerodigestive tract pathology.
Since this early report, the development of TORS in its
various human applications has been steadily progressing
with feasibility studies conﬁrming the safety and usability
of this technology in live human patients [5, 6]. Given the
beneﬁt of inﬁeld optics provided by the robot-mounted
double video endoscope, line-of-sight issues associated with
more traditional transoral techniques are overcome with
the use of TORS. This factor, combined with the valuable
3-dimensional imagery, tremor ﬁltration and the resultant
precision movements translated from the console to the
robotic instruments at the operative site, allow for accurate
dissection of tissue planes in a way not previously possible.
Various reports of the use of TORS in benign disease
processes have been published in the literature [7–10],
however, the majority of reports have concentrated on the
application of TORS in patients with mucosal malignancies,
particularlyofthelarynxandoropharynx[11–14].Emerging
evidence suggests that eﬀective primary surgical manage-
ment of these malignancies may provide an opportunity
for deintensiﬁcation of adjuvant treatments with resultant
improvements in patient’s posttreatment quality of life,
without compromising oncologic outcomes.
The aim of the current review is to provide an evaluation
of the existing literature with regards to the oncologic and
functional outcomes following treatment of OPSCC with
minimally invasive surgery and in particular, TORS.
2. Methods
A literature search was conducted using PUBMED and
MEDLINE with search parameters including (transor-
al[Title] AND ((“robotics”[MeSH Terms] OR “robotics”[All
Fields] OR ”robotic”[All Fields]) OR robot[All Fields]
OR telerobot[All Fields] OR (“robotics”[MeSH Terms] OR
“robotics”[All Fields] OR “telerobotics”[All Fields]) OR
robot-assisted[Title])) OR TORS[Title].
The references of the identiﬁed studies were reviewed
further for completeness. In addition, studies relating to the
useofTLMwereidentiﬁedtofacilitateacompleteevaluation
of the evidence base for the current role of MIS in the
management of OPSCC.
Only those studies dealing speciﬁcally with the manage-
ment of patients with HNSCC were included, with descrip-
tions of TORS for benign disease, nonmucosal malignancies
of the upper aerodigestive tract, novel applications of TORS
and descriptions of cadaveric studies all being excluded.
Speciﬁcally, data relating to the evaluation of quality of life,
oncologic and functional outcomes in the identiﬁed studies
was reviewed.
3. Results
Sixty-nine results were identiﬁed for review of which the
references were further evaluated for potential inclusion in
the analysis. Of particular note, studies related to the use
of transoral laser microsurgery were included for complete
review of minimally invasive surgery in the treatment of
OPSCC.
Sixteen studies were excluded as they were not related
to the application of TORS in patients with HNSCC. Forty
studies addressed the role of TORS in treatment of head
and neck tumors and in particular, 17 studies commented
directly on the use of TORS in patients with OPSCC.
Six studies were identiﬁed that investigated quality of life
and functional outcomes following TORS for treatment of
HNSCC/OPSCC with a further seven discussing feasibility
aspects including setup and operative times (Table 1).
3.1. Feasibility. The initiation of new TORS programs,
generally established in conjunction with robotic programs
in other surgical specialties, has repeatedly demonstrated
success in establishing safe and eﬃcient robotic services
for head and neck oncology units [15–19]. Operative setup
t i m e sh a v eb e e nr e p o r t e dt ot a k eb e t w e e n2m i n u t e sa n d
140minutes.Generally,averagesetuptimesafterpreliminary
experience within the TORS team are under 30 minutes.
Further demonstration of the increased eﬃciency following
the introduction of TORS to a department is documented
in the data from Moore et al. who signiﬁcantly improved
the setup time after their initial experience, suggesting that
the learning curve for operative eﬃciency is complete after
approximately 10 patients [14]. The average operative time
across all 7 studies is just under 75 minutes.
For patients who require free ﬂap reconstruction of the
ablative defect, feasibility studies and initial case series de-
tailing free tissue transfers via minimally invasive surgical
approaches and robotic-assisted microanastomotic tech-
niques have also demonstrated reliable perioperative out-
comes [17, 20–25].
3.2. Oncologic Outcomes. In excess of 500 patients receiving
TORS to manage OPSCC have been reported across 17
studies. A summary of the TORS literature relating to the
oncologic outcomes in patients with OPSCC is presented
in Table 2. Generally, these studies are retrospective in
nature and report on highly selected patients. Many reﬂect
treatment of advanced stage disease by virtue of N-positivity
with associated early T-classiﬁcation: several trials report
only on the treatment of T1-2 lesions with various stages
of cervical disease [12, 16, 26, 27]. These factors makeISRN Oncology 3
Table 1: Setup and operative times for TORS.
Study Complete setup time (minutes) Operative time (minutes)
O’Malley et al. [12] (3patients) Ave—44 Ave—105
Range—38–52 Range—91–131
Weinstein et al. [11] (27patients) Ave—9 Ave—103
Range—2–22 Range—26–233
Genden et al. [16] (18patients) Ave—55 Ave—84
Range—20–140 Range—45–150
Park et al. [27] (5patients) Ave—19 Ave—44
Range—15–25 Range—40–50
Moore et al. [14] (45patients) Ave 1st 10–69 Ave—72
Range—54–59 Range—45–320
Ave 2nd 35–22 Ave—71
Range—14–28 Range—6–309
Lawson et al. [19] (24patients) Ave—24 Ave—67
Range—10–60 Range—12–180
Aubry et al. [15] (17patients) Ave—21 Range—10–50 Ave—40
Range—10–90
Average operative time: 75
generalizations and direct comparisons to the nonsurgical
literature diﬃcult.
Nonetheless, preliminary data relating to local control,
disease-speciﬁc survival, and overall survival using upfront
TORS is encouraging, with early overall survival rates at
1 year exceeding 90% with emerging 2-year survival data
between 80% and 90% [13, 20, 28, 29]. Cohen et al. reported
1 and 2 year overall survival rates among a 50 patient cohort
of 95.7% and 80.6%, respectively. Thirty-nine patients had
T1/T2 lesions (78%), 8 had T3 lesions (16%), and 3 had T4
lesions (6%), with this low primary tumor volume further
demonstratedbythefactthatonlyasinglefreetissuetransfer
was required for reconstruction of the ablative defect [13].
Ongoing eﬀorts at other institutions have replicated these
early survival results, with Genden et al. demonstrating an
overall survival of 90% amongst their cohort of 30 patients
treated with primary TORS for HNSCC, whilst White et
al. recorded a 86.5% 2 year overall survival for 71 patients
undergoing TORS as part of treatment for HNSCC of all
subsites(87%patientshadOPSCC)[20,29].Inbothofthese
studies, a majority of patients again had advanced stage dis-
easewithearlyT-stagestatusandsmallvolumenodaldisease.
These oncologic outcomes with TORS largely mirror the
experience reported in the TLM literature with patient pop-
ulations again largely demonstrating early T-classiﬁcation,
deintensiﬁed adjuvant treatment recommendations based
on pathological staging, and impressive oncologic control
(Table 3). Steiner was one of the ﬁrst to report on this in
2003withareporton48patientstreatedformostlyadvanced
stageOPSCCinvolving the baseofthe tonguedemonstrating
a local control rate over 5 years of 85% [30]. Most recently,
Haughey et al. have published multicenter data on 204
patients treated with TLM ± adjuvant therapy for advanced
s t a g eO P S C C ,w i t h2a n d5y e a ro v e r a l ls u r v i v a lr a t e so f8 9 %
and 78%, respectively, and a local control of 97% [31]. Adju-
vant treatment was avoided in 26%, with the remaining 150
patients receiving adjuvant treatment of which 33 required
chemoradiotherapy. Although adjuvant radiotherapy was
associated with improved overall survival, the addition of
chemotherapy did not signiﬁcantly impact on survival.
This potential to deintensify treatment based on success-
ful surgical control of the primary tumor burden has led to
retrospective analysis of the experience in some centers with
single modality treatment of OPSCC. Grant et al. reported
in 2009 their experience with 69 patients with select mostly
early T-stage OPSCC who did not receive adjuvant therapy
(64% not indicated and 36% oﬀered but declined) [32].
The 5-year overall survival rate was 86% with no patients
requiring either tracheostomy of gastrostomy tube.
3.3. Functional Outcomes. It remains unclear whether a
subset of patients with OPSCC can be treated with primary
surgery in order to achieve superior functional results
with deintensiﬁcation of adjuvant treatment. Following on
from Steiner’s early work the use of TLM has repeatedly
demonstrated impressive functional outcomes with low rates
of gastrostomy dependency, decannulation and high quality
of life scores on questionnaire assessment. These results are
summarized in Tables 3 and 4.
Early TORS data supports these impressive functional
outcomes with most series reporting 1-year gastrostomy-
tube rates under 10% and long-term rates of 0% for patients
treated with upfront surgery [14, 20, 28, 33]( Table 5).
Higher rates of gastrostomy tube dependency have been
reported in TORS case series including all HNSCC subsites
with typically higher swallowing dysfunction observed in
patients with laryngeal malignancies [1, 2].4 ISRN Oncology
Table 2: Oncologic outcomes following TORS for OPSCC.
Study Number of
cases Primary site Pathological
stage HPV status Followup period
(mean) Oncologic outcomes
Cohen et al. [13] (Ap r ’10) 50 Oropharynx T1/2: 39 HPV-neg: 13 HPV-neg:
23.0mths
1yr: 95.7% (45/47)
T3: 11 2yr: 80.6% (25/31)
HPV-pos: 37 HPV-pos:
24.8mths
N0: 9
N1: 21
N2a: 0
N2b: 20
N2c: 0
N3: 0
Genden et al. [20] (Aug ’11) 30 27 oropharynx
(90%) T1/2: 30/30 N/A 20.4mths 18mth:
1 larynx (3.3%) locoregional control:
91%
1 oral cavity
(3.3%) N0: 6 distant control: 93%
1 hypopharynx
(3.3%) N1: 10 DFS: 78%
N2a: 5 OS: 90%
N2b: 7
N2c: 2
N3: 0
Weinstein et al. [28] (Nov ’10) 47 Oropharynx T1/2: 36 N/A 26mths Overall:
T3/4: 11 1yr: 96% (45/47)
2yr: 82% (27/33)
N0: 1 DFS:
N1: 24 1yr: 96% (45/47)
N2a: 1 2yr: 79% (26/33)
N2b: 19
N2c: 2
N3: 0
White et al. [29] (Dec ’10) 89 77 oropharynx
(87%) T1/2: 71 N/A 26mths
(median) DFS (entire cohort)
10 larynx (11%) T3/4: 18 2 years: 86.3%
2 oral cavity
(2%)
N0: 27 DFS (primary TORS
cohort)
N1: 8 2 years: 89.3%
N2a: 11
N2b: 26
N2c: 12
N3: 4
3.4. The Role of HPV. A further confounder in the manage-
ment of OPSCC is the role of HPV in disease pathogenesis
and signiﬁcance as a prognostic factor, apparently irrespec-
tive of treatment modality [13, 34–36]. The exact incidence
of HPV infection and its impact on patients with OPSCC
is still being elucidated in prospective trials after having
initially been appreciated in retrospective studies. Ang et al.
published their experience in the treatment of 323 patientsISRN Oncology 5
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Table 4: Gastrostomy tube dependency rates following TORS—
long and short term.
Study Short term 1 Year 2 Years
Weinstein et al. [28] (2010) 2.40% 0%
Moore et al. [14] (2009) 18% 0% 0%
Iseli et al. [33] (2009) 9.50%
Genden et al. [20] (2011) 0% 0%
with locally advanced OPSCC [37]. The HPV-positive rate
was 63.8% (206/323); HPV-positivity was associated with a
signiﬁcant relative reduction in the risk of death of 58%,
translating to an 82.4% survival rate at 3 years compared
to 57.1% in those patients HPV-negative. This signiﬁcant
survival advantage was also demonstrated Nichols et al. in
2010reportingon68patientswithOPSCC,ofwhom53were
found to be HPV-positive (78%) [38]. Patients who were
HPV-positive were 5 times less likely to develop recurrence
and 60% less likely to die of disease when compared to their
HPV-negative counterparts.
Weinstein et al. also reported on 50 patients treated for
OPSCC with an HPV-positive rate of 74% (37/50). In this
series of patients treated with upfront TORS, the disease-
speciﬁc survival of patients with HPV-positive OPSCC at 1-
year and 2-years was 97% and 90%, respectively. However,
the HPV-negative cohort in this primary surgical series
demonstrated equal oncologic control with disease-speciﬁc
survival rates at both 1-year and 2-years of 100%.
4. Discussion
The management of patients with OPSCC continues to
evolve with both advances in therapeutic regimens and
evolution of our understanding of the underlying disease
pathophysiology. Early surgery-based treatment paradigms
have been largely abandoned with the general adoption
of nonsurgical regimens supported by an evidence base
demonstrating superior functional outcomes whilst retain-
ing comparable survival results [39–41].
Paralleling the improvements in surgical technique, the
natural evolution of radiotherapy has resulted in a decrease
in treatment-related morbidity. Reﬁnement of targeted
3D conformal radiotherapy methods such as intensity-
modulated radiotherapy (IMRT) has allowed increased pre-
cision in delivery of radiotherapy to patients with HNSCC
with associated decreases in adverse sequelae [42]. Temper-
ing these beneﬁts, however, has eﬀects related to escalation
of treatments in an eﬀort to improve survival outcomes.
Meta-analysis data have demonstrated improved survival
with altered fractionated regimens and/or the addition of
chemotherapy, at the expense of signiﬁcant increases in
treatment related toxicities, particularly acute mucositis and
long-term swallowing dysfunction [43–46].
As the etiologic factors involved in the development
of OPSCC continue to be elucidated one variable that
has proven immensely signiﬁcant is the role of human
papillomavirus (HPV). This HPV epidemic has interestingly
occurred during the same period as the widespread adoption
of chemoradiotherapy as standard of care treatment for
advanced stage OPSCC. This has managed to blur the lines
somewhat with respect to whether these improved outcomes
are secondary to treatment modiﬁcations or reﬂective of
a naturally improved survival rate in patients with HPV-
positive disease. Furthermore, the HPV-positive OPSCC
patient has been deﬁned as typically younger with lower
rates of signiﬁcant medical comorbidities [47]. Combined
with improved rates of cure this young, high functioning
population requires special consideration given that any
treatment related side eﬀects may need to be lived with for
extended periods of time.
Oncologic outcomes in patients with HPV-positive
OPSCC remain similar regardless of treatment approach.
Therefore, an appreciation of functional outcomes repre-
sents a signiﬁcant and fundamental consideration when
formulatingmanagementrecommendations.Transfacialand
transmandibular surgical approaches to the oropharynx
carry potential morbidity and have been demonstrated on
retrospective analysis to be associated with poor functional
outcomes when compared to radiotherapy [39–41]. Both
TLM and TORS facilitate surgical access to the lower subsites
of the upper aerodigestive tract without need for traditional
methods requiring open surgical approaches. Repeatedly,
these MIS techniques have both demonstrated sound onco-
logic and functional/quality of life outcomes [14, 28, 48–
52]. Potential beneﬁts also exist with respect to adjuvant
treatment deintensiﬁcation and avoidance altogether in
select circumstances [32, 53–55].
Comparisons of outcomes after TORS versus chemora-
diotherapy across studies are hampered by diﬀerences in
baseline patient populations, selection, and treatment tech-
nique. Nonetheless, rates of gastrostomy tube dependency
after chemoradiotherapy have typically been reported as
between 9% to 39% in patients treated with chemoradio-
therapy [56–59]. Critical analysis of the chemoradiotherapy
literature reveals a patient population that typically diﬀers
fromtherecentMISliteraturewithinclusionofpatientswith
unresectable (T4b) and/or bulky primary disease (greater
than 4cm), and typical exclusion of early primary disease
such as in the series reported by the Radiation Therapy
Oncology Group [37]. Therefore, direct comparisons across
these reported functional outcomes are diﬃcult.
The promising impact of TORS on the quality of life and
survival outcomes of OPSCC patients remains an important
clinical question that requires higher levels of support-
ing evidence. A recent surgical consensus statement (the
“IDEAL” guidelines) suggests that randomized comparisons
be carried out wherever possible, once adequate pretrial
data are available [60]. Through centres in London and
Ottawa,Ontario,theORATORStudy(Oropharyngealcancer
Radiation versus TORS) is planned to open in early 2012.
This study will randomize OPSCC patients to curative intent
treatment with either upfront TORS ± adjuvant treatment
versus nonsurgical treatment, with the primary endpoint
being superior swallowing function at one year in the
TORS arm as determined by the MD Anderson Dysphagia
Inventory (MDADI).ISRN Oncology 9
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Ultimately, ORATOR aims to assist in the identiﬁcation
of OPSCC patients who might be best served by upfront
surgery. Adapting data from other head and neck subsites
we understand that in a select group of “surgical respon-
ders” chemoradiotherapy represents a suboptimal treatment
approach due to either lack of response in locoregional dis-
ease control or excessive treatment-related side eﬀects and
morbidity. Further, deﬁning the “surgical responder” in pa-
tients with OPSCC is perhaps even more important than
other subsites such as the larynx given the relative lack of
success with surgical salvage. Combined with the work of
others, ORATOR can hopefully work to identify the ideal
OPSCC patients for upfront TORS, with the realization that
chemoradiotherapy will still represent an excellent treatment
option for the “nonsurgical responder.”
Ultimately, providing truly accurate risk assessment will
require a clearer understanding of the underlying molec-
ular genetics of HNSCC. Only then can patients be risk
stratiﬁed with relative certainty utilizing both clinical and
genetic evidence to guide treatment plans. Recent high-
throughput genetic sequencing publications in science by
Agrawal and Stransky provide exciting insights into a future
that promises genetically guided management to optimize
survival and minimize treatment-related morbidity [61, 62].
Further, current vaccination programs aimed at reducing
HPV transmission within the wider community provide an
exciting opportunity to impact signiﬁcantly on the incidence
of OPSCC.
5. Conclusion
The continued development of minimally invasive surgical
techniques such as TORS oﬀers a signiﬁcant opportunity to
impact positively on patient quality of life and posttreatment
function whilst retaining satisfactory oncologic control.
Initial feasibility and case series reports are encouraging but
require further validation through well-designed random-
ized control trials prior to widespread shifts in accepted
treatment paradigms.
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